Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease

BACKGROUND AND AIMS: Vedolizumab (VDZ) is effective for Crohn’s disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. METHODS: Phase 3 clinical trial data on VZD for CD were used to pr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Inflamm Bowel Dis
Hlavní autoři: Waljee, Akbar K, Liu, Boang, Sauder, Kay, Zhu, Ji, Govani, Shail M, Stidham, Ryan W, Higgins, Peter D R
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Future Directions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6231370/
https://ncbi.nlm.nih.gov/pubmed/29668915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy031
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky